Axitinib plus pembrolizumab is recommended as first-line therapy for patients with favorable-risk clear cell advanced renal cell carcinoma, according to an updated position statement from the Society for Immunotherapy of Cancer.
In a phase 3 trial, mitomycin gel for instillation showed a complete response rate of 59% of patients with low-grade upper tract urothelial cancer.
For men with newly diagnosed metastatic castration-resistant prostate cancer, starting with abiraterone plus prednisone followed by enzalutamide upon PSA progression significantly prolongs time to second PSA progression compared with the opposite sequence, a study found.
In a small study of patients without a history of bladder cancer who undergo radical nephroureterectomy for upper tract urothelial carcinoma, preoperative pyuria was associated with a 1.7-fold increased risk of intravesical recurrence, a study found.
